Trial record 1 of 47 for:    " January 23, 2008":" February 22, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Previous Study | Return to List | Next Study

TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy

This study has been completed.
Information provided by (Responsible Party):
Theratechnologies Identifier:
First received: January 23, 2008
Last updated: November 27, 2013
Last verified: November 2013

HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation, loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from the first Phase 3 multicenter, randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV- infected patients with excess of abdominal fat accumulation for 26 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with lesser changes in limb fat and subcutaneous adipose tissue (SAT). The present study is aimed at confirming the observations made during the first Phase 3 study.

Condition Intervention Phase
HIV Infections
Drug: Tesamorelin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

Resource links provided by NLM:

Further study details as provided by Theratechnologies:

Primary Outcome Measures:
  • Changes in Fasting Glucose [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Changes in 2 h Glucose OGTT [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Visceral Adipose Tissue (VAT) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Subjects underwent a single-slice abdominal computerized tomography (CT) to determine abdominal visceral and subcutaneous faté

Other Outcome Measures:
  • Triglycerides [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Total Chol. /HDL Chol. Ratio [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 265
Study Start Date: August 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tesamorelin 12 months
Tesamorelin 2 mg/day for 12 months
Drug: Tesamorelin
No Intervention: Placebo
Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
Experimental: Tesamorelin 6 months
Placebo 6 months - Tesamorelin 2 mg/day for 6 months
Drug: Tesamorelin


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.
  • Signed informed consent before any trial-related activities.

Exclusion Criteria:

  • Fasting blood glucose >8.33 mmoL (150 mg/dL) at the end of the TH9507-CTR-1011 study.
  Contacts and Locations
Please refer to this study by its identifier: NCT00608023

  Show 49 Study Locations
Sponsors and Collaborators
Principal Investigator: Steven Grinspoon, MD Massachusetts General Hospital
  More Information

No publications provided by Theratechnologies

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Theratechnologies Identifier: NCT00608023     History of Changes
Other Study ID Numbers: TH9507-CTR-1012
Study First Received: January 23, 2008
Results First Received: November 27, 2013
Last Updated: November 27, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Theratechnologies:
Abdominal fat accumulation
Growth hormone releasing hormone
HIV-associated lipodystrophy
Treatment experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
HIV-Associated Lipodystrophy Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Growth Hormone-Releasing Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions processed this record on April 15, 2014